Skip to content
Menu

INOVIO Submits Conditional Marketing Authorization Application To EMA For VOCERYQ In Adults with Recurrent Respiratory Papillomatosis

Benzinga Newsdesk 9 hours ago

FDANews

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

VOCERYQ™, the first FDA-approved plasmid DNA-based immunotherapy, received FDA accelerated approval on October 30, 2026Recurrent Respiratory Papillomatosis (RRP) is a rare, debilitating HPV-related disease with high

  • VOCERYQ™, the first FDA-approved plasmid DNA-based immunotherapy, received FDA accelerated approval on October 30, 2026
  • Recurrent Respiratory Papillomatosis (RRP) is a rare, debilitating HPV-related disease with high unmet need in Europe

Read at benzinga.com